Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Ken Bahk, Tim Patno, Chad Mirkin, Warren Kocmond

Premium

Nanosphere said this week that it has appointed Ken Bahk as chief strategy officer, a new position, and that CTO Tim Patno and board member Chad Mirkin will be leaving the company.

Bahk was part of Nanosphere's initial team, and served with the company until 2008. In the new post, he will be responsible for driving strategic plans and revenues in molecular diagnostics.

He currently is a director of investments at Lurie Investments, where he focuses on the diagnostics and life sciences areas. He also formerly was chair of strategic opportunities for the Association for Molecular Pathology.


Cepheid disclosed during its first-quarter earnings call last week that Warren Kocmond will join the company on May 6 as executive vice president of global operations.

Kocmond is currently vice president of global operations for Lam Research, and has previously served as executive vice president of memory products at Verigy; CEO of Electroglas; and senior vice president of global operations at Affymetrix.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.